Dose-enhanced combined priming regimens for refractory acute myeloid leukemia and middle-and-high-risk myelodysplastic syndrome: a single-center, retrospective cohort study

OBJECTIVE: To assess chemotherapeutic regimens for refractory acute myeloid leukemia (AML) and middle-and-high-risk myelodysplastic syndrome (MDS). METHODS: Between 2004 and 2014, 44 patients with refractory AML and 36 patients with MDS were treated with new priming regimens (CHAG, CHTG, CHMG, or CT...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Onco Targets Ther
Autori principali: Ma, Xiaorong, Wang, Jin, Xu, Yan, Zhang, Wanggang, Liu, Jie, Cao, Xingmei, He, Aili, Wang, Fangxia, Gu, Liufang, Lei, Bo, Wang, Jianli
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove Medical Press 2016
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4920259/
https://ncbi.nlm.nih.gov/pubmed/27382304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S96427
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi